Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.36
- Piotroski Score 2.00
- Grade Buy
- Symbol (CGEN)
- Company Compugen Ltd.
- Price $1.65
- Changes Percentage (0.31%)
- Change $0.01
- Day Low $1.63
- Day High $1.67
- Year High $3.03
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $4.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.18
- Trailing P/E Ratio -11.72
- Forward P/E Ratio -11.72
- P/E Growth -11.72
- Net Income $-18,754,000
Income Statement
Quarterly
Annual
Latest News of CGEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Chinese stocks could rally 15% as more stimulus spurs a GDP growth spurt next year, SocGen says
Société Générale predicts a potential 5% growth in China's GDP next year due to expected stimulus measures. Recent monetary actions have already led to increased investor optimism, with a forecast...
By Yahoo! Finance | 1 month ago -
A key US consumer indicator has dipped to 'crisis levels,' SocGen says
The US personal savings rate has dropped below 3%, signaling strong consumer spending. However, this could lead to a rise in savings and a potential economic slowdown, reminiscent of pre-2008 financia...
By Business Insider | 1 month ago -
Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?
Compugen Ltd. is a clinical-stage therapeutic discovery and development company nearing breakeven. Analysts predict the company may become profitable by 2025, with a 50% year-on-year growth rate. Desp...
By Yahoo! Finance | 2 months ago
